GlassScriptPhysician profile
Brooke L Tobia
NPI 1568740918
$14,935.67
in general payments reported to CMS, 2019-2025
49 companies · $3,927 in 2025
The $3,927 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,302 · 2022: $2,735 · 2023: $3,004 · 2024: $2,968 · 2025: $3,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,898.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,912.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,853.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,445.00 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,166.40 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,147.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $918.64 | 2021-2025 | |
| Esperion Therapeutics, INC. | $633.63 | 2021-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $522.83 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.75 | 2021-2025 | Jardiance, Tradjenta |
| Paratek Pharmaceuticals, INC. | $427.01 | 2022-2025 | Nuzyra, Xhance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.10 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $414.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $384.17 | 2021-2025 | |
| Exact Sciences Corporation | $379.61 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $355.29 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $320.04 | 2021-2023 | |
| Lundbeck LLC | $243.32 | 2022-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $179.16 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $170.63 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $128.72 | 2022-2025 | Veozah |
| Boston Scientific Corporation | $127.55 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $118.83 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.73 | 2022-2024 | Eohilia, Trintellix |
| Janssen Pharmaceuticals, INC | $82.24 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $79.88 | 2023 | Trudhesa |
| Indivior INC. | $79.60 | 2021-2025 | Sublocade |
| Daiichi Sankyo INC. | $73.86 | 2022-2025 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $73.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $66.60 | 2024-2025 | Fanapt, Hetlioz |
| Medtronic, INC. | $60.27 | 2025 | Inceptiv |
| Alkermes, INC. | $56.08 | 2021 | |
| Allergan, INC. | $50.99 | 2021-2022 | |
| Ucb, INC. | $45.09 | 2024 | Nayzilam |
| Orexo US, INC. | $44.36 | 2022-2024 | Zubsolv |
| Phathom Pharmaceuticals, INC. | $42.38 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $41.85 | 2021-2023 | Austedo |
| Inspire Medical Systems, INC. | $41.34 | 2024-2025 | Inspire |
| Nevro Corp. | $30.48 | 2022 | |
| Horizon Therapeutics Plc | $24.91 | 2021 | |
| Pulmonx Corporation | $24.62 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Corcept Therapeutics | $19.72 | 2025 | Korlym |
| Phadia US INC. | $19.71 | 2021 | |
| Merck Sharp & Dohme LLC | $17.23 | 2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $14.70 | 2022 | |
| Eisai INC. | $14.56 | 2021 | |
| Abbott Laboratories | $13.76 | 2021 | |
| Alfasigma USA, INC. | $13.08 | 2022 | |
| Medicomp INC | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Tobia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.